Human leukocyte antigen DR3 (HLA-DR3)

HLA-DR3 is a specific serotype of the human leukocyte antigen DR (HLA-DR) family, which belongs to the major histocompatibility complex (MHC) class II receptors. It is primarily expressed on antigen-presenting cells such as B cells, macrophages, and dendritic cells, where its fundamental role is to present exogenous peptides to CD4+ T-helper cells to initiate an adaptive immune response (Source: UniProt, StatPearls). HLA-DR3 is highly significant in clinical immunology due to its strong genetic association with a variety of autoimmune disorders, including Type 1 diabetes, systemic lupus erythematosus (SLE), and Graves' disease (Source: PubMed, NIH). In these conditions, HLA-DR3 molecules may inappropriately present self-peptides, leading to the breakdown of immune tolerance and subsequent tissue damage. While it is not a traditional drug target in the sense of a small molecule binding site, it is a critical focal point for therapeutic strategies involving T-cell modulation and peptide-based vaccines designed to induce tolerance (Source: Wikipedia, Peer-reviewed journals). Understanding a patient's HLA-DR3 status is often essential for risk stratification and the development of personalized immunotherapies.

Other names

HLA-DRB1*03MHC class II antigen DR3DR3HLA-DRB1*03:01

Modulation of T-cell activation by interfering with antigen presentation or costimulatory signals; non-specific immunosuppression to reduce HLA-mediated inflammatory cascades.